Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-Mediated Restriction

• Published in: Cell reports (Cambridge) Vol. 5; no. 4; pp. 895 - 908
• Main Authors: Lin, Tsai-Yu, Chin, Christopher R., Everitt, Aaron R., Clare, Simon, Perreira, Jill M., Savidis, George, Aker, Aaron M., John, Sinu P., Sarlah, David, Carreira, Erick M., Elledge, Stephen J., Kellam, Paul, Brass, Abraham L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 27.11.2013; Cell Press; Elsevier
• Subjects: Acetylcholine - pharmacology; Amphotericin B - administration & dosage; Amphotericin B - adverse effects; Animals; Anti-Bacterial Agents - pharmacology; Antifungal Agents - administration & dosage; Antifungal Agents - adverse effects; Antigens, Differentiation - metabolism; Biological Transport - drug effects; Cell Fusion; Cell Line; Cell Membrane - drug effects; Cell Membrane - metabolism; Chlorocebus aethiops; COS Cells; HeLa Cells; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype - immunology; Influenza, Human - immunology; Interferons - immunology; Membrane Proteins - antagonists & inhibitors; Membrane Proteins - genetics; Mice; Mice, Inbred C57BL; Mice, Knockout; Nystatin - pharmacology; Orthomyxoviridae Infections - immunology; RNA Interference; RNA, Small Interfering; Sodium - metabolism; Tetraethylammonium - pharmacology; Virus Internalization - drug effects; Virus Replication - drug effects

The IFITMs inhibit influenza A virus (IAV) replication in vitro and in vivo. Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication. Consistent with its neutralization of IFITM3, a clinical preparati...